- Home
- NDLS vs GDTC Comparison
NDLS vs GDTC Comparison
Compare NDLS & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- GDTC
- Stock Information
- Founded
- NDLS 1995
- GDTC 2018
- Country
- NDLS United States
- GDTC Singapore
- Employees
- NDLS N/A
- GDTC N/A
- Industry
- NDLS Restaurants
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- GDTC Health Care
- Exchange
- NDLS Nasdaq
- GDTC Nasdaq
- Market Cap
- NDLS 29.8M
- GDTC 24.2M
- IPO Year
- NDLS 2013
- GDTC 2023
- Fundamental
- Price
- NDLS $0.71
- GDTC $2.56
- Analyst Decision
- NDLS Buy
- GDTC
- Analyst Count
- NDLS 2
- GDTC 0
- Target Price
- NDLS $3.00
- GDTC N/A
- AVG Volume (30 Days)
- NDLS 118.3K
- GDTC 112.7K
- Earning Date
- NDLS 11-05-2025
- GDTC 01-01-0001
- Dividend Yield
- NDLS N/A
- GDTC N/A
- EPS Growth
- NDLS N/A
- GDTC N/A
- EPS
- NDLS N/A
- GDTC N/A
- Revenue
- NDLS $494,752,000.00
- GDTC $573,193.00
- Revenue This Year
- NDLS $1.19
- GDTC $5.37
- Revenue Next Year
- NDLS N/A
- GDTC N/A
- P/E Ratio
- NDLS N/A
- GDTC N/A
- Revenue Growth
- NDLS N/A
- GDTC 63.03
- 52 Week Low
- NDLS $0.55
- GDTC $1.65
- 52 Week High
- NDLS $1.74
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- NDLS 52.15
- GDTC 66.69
- Support Level
- NDLS $0.60
- GDTC $1.95
- Resistance Level
- NDLS $0.68
- GDTC $2.43
- Average True Range (ATR)
- NDLS 0.04
- GDTC 0.22
- MACD
- NDLS 0.01
- GDTC 0.05
- Stochastic Oscillator
- NDLS 68.27
- GDTC 77.91
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.